1. A 74-year-old man with end-stage renal disease presents with serum potassium of 7.1 mEq/L and peaked T waves on ECG. The team administers calcium gluconate 1 g IV over 10 minutes as the first intervention. Which of the following most precisely describes the pharmacodynamic action of calcium gluconate in this setting?
A) It activates Na/K-ATPase in skeletal muscle, shifting potassium intracellularly and lowering serum potassium by 0.5–1.5 mEq/L within 15–30 minutes
B) It alkalinizes the plasma, driving potassium into cells in exchange for hydrogen ions and reducing ECG manifestations of hyperkalemia
C) It raises the threshold potential of cardiac myocytes, increasing the gap between the resting membrane potential and the action potential threshold; this reduces myocardial excitability without altering serum potassium, with onset in 1–3 minutes and duration of 30–60 minutes
D) It chelates extracellular potassium directly, reducing the electrochemical gradient for potassium efflux from myocytes and stabilizing the resting membrane potential
E) It competitively inhibits potassium binding at cardiac membrane channels, reducing the depolarizing effect of hyperkalemia on the conducting system
ANSWER: C
Rationale:
Calcium gluconate acts by raising the threshold potential of cardiac myocytes — the voltage that must be reached before an action potential fires. In hyperkalemia, the resting membrane potential is less negative (depolarized) because the reduced extracellular-to-intracellular potassium gradient decreases the driving force for potassium efflux, bringing the resting potential dangerously close to the threshold and creating spontaneous depolarization risk. Calcium ions increase the threshold potential, restoring the gap between resting and threshold potentials and reducing myocardial excitability. Onset is 1–3 minutes; duration is 30–60 minutes. Critically, calcium gluconate does not lower serum potassium, does not shift potassium into cells, and does not remove potassium from the body — it is solely a cardiac membrane stabilizer. Definitive potassium removal must always follow.
Option A: Option A is incorrect: Na/K-ATPase activation with resultant intracellular potassium shift is the mechanism of insulin, not calcium gluconate; calcium has no direct effect on Na/K-ATPase activity.
Option B: Option B is incorrect: plasma alkalinization driving potassium into cells via hydrogen-potassium exchange describes a component of the bicarbonate mechanism in severe acidemia, not calcium gluconate's action.
Option D: Option D is incorrect: calcium does not chelate extracellular potassium; chelation of ionized cations in the tubular lumen is the mechanism of foscarnet (for calcium and magnesium), not calcium gluconate.
Option E: Option E is incorrect: calcium does not competitively inhibit potassium at membrane channels; its mechanism is surface charge neutralization of the lipid bilayer, which raises the threshold potential rather than blocking specific potassium channels.
2. During resuscitation of a patient with severe hyperkalemia and hemodynamic compromise, the team has only peripheral IV access. A nurse asks whether calcium chloride can be substituted for calcium gluconate. Which of the following best describes the clinically relevant pharmacological difference between these two formulations that determines the answer?
A) Calcium chloride contains approximately three times the elemental calcium per gram compared with calcium gluconate and has equivalent cardiac membrane-stabilizing potency per dose; however, it requires central venous access because extravasation causes severe tissue necrosis, making peripheral administration unsafe
B) Calcium chloride has a slower onset of action than calcium gluconate because it must first be metabolized by hepatic glucuronidase to release ionized calcium, making it unsuitable for acute emergencies regardless of access route
C) Calcium chloride and calcium gluconate contain identical amounts of elemental calcium per gram and are interchangeable via either peripheral or central venous access; the choice is solely determined by local formulary availability
D) Calcium gluconate requires central venous access because its gluconate component is a potent vasoconstrictor that causes peripheral vein spasm, whereas calcium chloride is the safer peripheral formulation
E) Calcium chloride is contraindicated in hyperkalemia because chloride ions competitively inhibit potassium excretion at the distal tubule, worsening the underlying electrolyte imbalance
ANSWER: A
Rationale:
Calcium chloride contains approximately three times the elemental calcium per gram compared with calcium gluconate — 1 g of calcium chloride provides roughly 272 mg of elemental calcium, whereas 1 g of calcium gluconate provides roughly 90 mg. Both formulations produce equivalent cardiac membrane stabilization when equimolar elemental calcium doses are given, but the higher calcium concentration per gram of calcium chloride means that smaller volumes achieve the same effect, which can be advantageous in fluid-restricted patients. The critical clinical limitation of calcium chloride is that it requires central venous access: extravasation into subcutaneous tissue causes severe chemical burns and tissue necrosis due to its highly caustic pH. Calcium gluconate, which releases ionized calcium more slowly through hepatic metabolism of the gluconate moiety, is substantially less caustic and is safer for peripheral administration, though even gluconate extravasation warrants monitoring.
Option B: Option B is incorrect: while calcium gluconate does require hepatic conversion of the gluconate ligand to release free ionized calcium (making its ionized calcium release slightly slower), this is not a reason to call it unsuitable for acute emergencies — it is routinely used as first-line therapy; the distinction is about peripheral safety, not speed of onset.
Option C: Option C is incorrect: calcium chloride and calcium gluconate are not equivalent in elemental calcium content per gram; calcium chloride provides approximately three times more elemental calcium per gram, and they are not interchangeable gram-for-gram.
Option D: Option D is incorrect: the requirement for central access applies to calcium chloride, not calcium gluconate; it is the chloride salt's caustic properties that mandate central access, not gluconate's pharmacological effects on vasculature.
Option E: Option E is incorrect: calcium chloride does not worsen hyperkalemia through tubular chloride-potassium competition; no such mechanism exists, and calcium chloride is used clinically for hyperkalemia management.
3. A 69-year-old woman with oliguric acute kidney injury has serum potassium of 6.9 mEq/L with ECG changes. She receives calcium gluconate, then insulin with dextrose, then nebulized albuterol. Her repeat potassium after these interventions is 5.8 mEq/L. The nephrology fellow explains to the team why ongoing management is still urgently required despite this improvement. Which of the following best explains the pharmacological basis for continued urgency?
A) Insulin, albuterol, and calcium gluconate all stimulate urinary potassium excretion through distinct tubular mechanisms, but their combined effect saturates the ROMK channel within 4–6 hours, causing potassium to reaccumulate at a rate faster than it was initially removed
B) The potassium-lowering effect of albuterol is mediated by beta-1 adrenergic receptors; once these receptors downregulate after repeated dosing, the drug loses efficacy and rebound hyperkalemia exceeds baseline levels
C) Calcium gluconate, insulin, and albuterol each carry a risk of paradoxical hyperkalemia with repeated dosing because they stimulate aldosterone secretion, which eventually overwhelms the intracellular shifting mechanism
D) The combination of insulin and albuterol produces permanent intracellular sequestration of potassium in skeletal muscle through irreversible phosphorylation of Na/K-ATPase; the potassium removed from the extracellular space will not return and no further intervention is required once the target serum level is achieved
E) All three agents administered — calcium gluconate, insulin, and albuterol — act by redistributing potassium into cells or stabilizing the cardiac membrane rather than removing potassium from the body; their effects are temporary, lasting 4–6 hours for insulin before potassium returns to the extracellular space, and definitive elimination via diuretics, cation exchangers, or dialysis has not been established
ANSWER: E
Rationale:
The distinction between redistribution and elimination is the central pharmacological principle governing acute hyperkalemia management. Calcium gluconate stabilizes the cardiac membrane by raising the threshold potential but removes no potassium from the body. Insulin drives potassium into skeletal muscle cells via Na/K-ATPase stimulation — a transient effect lasting 4–6 hours, after which potassium redistributes back to the extracellular space as the insulin effect wanes. High-dose albuterol drives potassium into cells via beta-2-mediated cAMP activation of Na/K-ATPase — similarly temporary, lasting 30–90 minutes to a few hours. None of these agents removes potassium from the body. In this oliguric patient, renal potassium excretion via diuretics is not viable, making a gastrointestinal cation exchanger (patiromer or sodium zirconium cyclosilicate) or hemodialysis the required definitive step. Failure to establish elimination leads to recurrent severe hyperkalemia when redistribution resolves.
Option A: Option A is incorrect: none of the three agents stimulates urinary potassium excretion; they are redistribution and membrane-stabilization agents only, and ROMK saturation is not the mechanism of potassium reaccumulation.
Option B: Option B is incorrect: albuterol's hyperkalemia-lowering effect is mediated by beta-2 adrenergic receptors on skeletal muscle, not beta-1 receptors; receptor downregulation producing rebound hyperkalemia exceeding baseline is not an established pharmacological phenomenon with standard acute dosing.
Option C: Option C is incorrect: none of these agents stimulates aldosterone secretion as a mechanism of action; albuterol at high doses causes tachycardia via beta-1 cross-stimulation but does not cause clinically significant aldosterone release sufficient to overwhelm potassium redistribution.
Option D: Option D is incorrect: insulin and albuterol do not cause permanent or irreversible intracellular potassium sequestration; Na/K-ATPase stimulation produces a transient shift that reverses as drug effect wanes, making ongoing management essential.
4. A hospitalized patient with CKD stage 4 and serum potassium of 6.1 mEq/L has received calcium gluconate and insulin-dextrose. The team wants to begin a potassium binder. The attending asks the resident to distinguish between patiromer and sodium zirconium cyclosilicate (SZC) in terms of mechanism, onset, and approved indications. Which of the following is the most accurate characterization?
A) Patiromer is a potassium-zirconium crystal that traps potassium throughout the gastrointestinal tract with an onset of approximately 1 hour; SZC is a calcium-zirconium polymer that acts only in the colon with an onset of 4–24 hours; both are approved for acute and chronic management
B) SZC is a highly selective potassium-zirconium crystal that traps potassium throughout the gastrointestinal tract via ion exchange with an onset of approximately 1 hour and regulatory approval for both acute and chronic hyperkalemia; patiromer is a non-absorbed calcium-zirconium polymer that binds potassium in the colon with an onset of 4–24 hours and approval for chronic management only
C) SZC and patiromer are both calcium-zirconium polymers with equivalent onset profiles of 2–4 hours; the principal difference is that SZC is dosed once daily and patiromer is dosed three times daily, making SZC preferred for outpatient adherence
D) Patiromer exchanges sodium for potassium in the gastrointestinal tract and is preferred in heart failure patients to avoid calcium loading; SZC exchanges calcium for potassium and carries a higher risk of hypercalcemia with prolonged use
E) Both patiromer and SZC bind potassium irreversibly in the colon and must be separated from other oral medications by at least 6 hours due to their high potential for drug-drug interactions mediated by gastrointestinal pH alteration
ANSWER: B
Rationale:
SZC (sodium zirconium cyclosilicate; Lokelma) is a highly selective inorganic crystal lattice that selectively captures potassium ions throughout the gastrointestinal tract via ion exchange, with an onset of approximately 1 hour. It has FDA approval for both acute hyperkalemia management (dosed 10 g three times daily for the first 48 hours in the acute correction phase) and chronic maintenance. Patiromer (Veltassa) is a non-absorbed organic polymer (calcium-zirconium based) that binds potassium in exchange for calcium in the colon, with an onset of 4–24 hours — too slow for acute emergencies. Patiromer is approved for chronic hyperkalemia management only. For this hospitalized patient where some degree of acute reduction is still desirable, SZC is the pharmacologically appropriate binder choice.
Option A: Option A is incorrect: the descriptions of the two agents are reversed — SZC is the potassium-zirconium crystal with 1-hour onset and broader approval, while patiromer is the calcium-zirconium polymer with slower onset acting in the colon; the approval designations are also inverted.
Option C: Option C is incorrect: SZC and patiromer do not have equivalent onset profiles; their onset kinetics differ substantially (1 hour vs. 4–24 hours), which is the clinically defining difference between them; dosing frequency differences do not explain the onset gap.
Option D: Option D is incorrect: patiromer exchanges calcium (not sodium) for potassium in the colon; SZC exchanges sodium and hydrogen for potassium (not calcium); the concern about sodium loading with SZC is modest and clinically relevant in some contexts, but the option's mechanism descriptions are both incorrect.
Option E: Option E is incorrect: while patiromer does have a drug interaction concern requiring separation from other oral medications (it can bind other drugs non-selectively), the mechanism is adsorption rather than pH alteration, and the characterization does not apply equally to SZC; stating both bind potassium irreversibly is also incorrect — the binding is exchangeable.
5. A 58-year-old woman with SIADH (syndrome of inappropriate antidiuretic hormone secretion) secondary to small cell lung cancer has a serum sodium of 113 mEq/L and has been symptomatic with confusion for approximately 3 days. She is started on 3% hypertonic saline. Which of the following best describes the correction rate limits that must govern her treatment and the neurological consequence of exceeding them?
A) The correction limit is 20 mEq/L in the first 24 hours; exceeding this rate risks cerebral edema from osmotic fluid shifts into neurons, causing herniation within hours of the overcorrection
B) The correction limit is 1–2 mEq/L per hour with no 24-hour ceiling; the primary risk of rapid correction is central pontine myelinolysis affecting only the pons, sparing extrapontine white matter structures
C) Correction should target 130 mEq/L within 24 hours in symptomatic patients; faster correction is associated with renal tubular acidosis rather than neurological injury
D) The current standard limits correction to 6–8 mEq/L in the first 24 hours and no more than 10–12 mEq/L in any 24-hour period; exceeding these limits in patients with chronic hyponatremia — where cerebral adaptation has occurred — risks osmotic demyelination syndrome, a devastating demyelinating injury of the pontine and extrapontine white matter
E) No specific correction rate limit exists for symptomatic hyponatremia; sodium should be raised as rapidly as possible to 135 mEq/L to reverse cerebral edema, with the rate determined only by patient tolerance of the hypertonic infusion
ANSWER: D
Rationale:
The correction rate for hyponatremia is the dominant safety variable governing treatment. The current evidence-based standard limits correction to 6–8 mEq/L in the first 24 hours, with an absolute maximum of 10–12 mEq/L in any 24-hour period. The rationale centers on cerebral adaptation: in chronic hyponatremia lasting more than 48 hours, brain cells extrude intracellular osmolytes (myoinositol, taurine, glutamine) to reduce intracellular osmolarity and prevent cell swelling. When serum osmolarity is then raised rapidly, water moves out of brain cells faster than osmolytes can be restored, causing osmotic shrinkage and myelin sheath disruption — osmotic demyelination syndrome (ODS). ODS affects both pontine (central pontine myelinolysis) and extrapontine white matter, causing dysarthria, dysphagia, spastic quadriparesis, and potentially locked-in syndrome. This patient's 3-day symptom duration confirms chronic hyponatremia with cerebral adaptation, making strict rate control essential. If overcorrection occurs, the response is desmopressin plus free water to re-lower sodium.
Option A: Option A is incorrect: the correction limit is 6–8 mEq/L per 24 hours (not 20 mEq/L); the risk of rapid correction in chronic hyponatremia is osmotic demyelination from myelin disruption, not cerebral edema from osmotic fluid influx — that is the risk of hyponatremia itself, not its correction.
Option B: Option B is incorrect: while hourly rate monitoring is part of management, there is a 24-hour ceiling (10–12 mEq/L maximum); ODS affects both pontine and extrapontine structures, not only the pons — the term "central pontine myelinolysis" is now considered an incomplete description.
Option C: Option C is incorrect: targeting 130 mEq/L within 24 hours would require a 17 mEq/L rise from 113 mEq/L, which substantially exceeds the safe limit; ODS, not renal tubular acidosis, is the neurological consequence of rapid correction.
Option E: Option E is incorrect: there is a specific and well-established correction rate limit for hyponatremia; rapid correction to 135 mEq/L in a chronic hyponatremia patient is one of the most dangerous errors in inpatient medicine and causes ODS, not resolution of cerebral edema.
6. A 45-year-old man presents with acute severe hyponatremia (serum sodium 118 mEq/L) of less than 24 hours duration, with active seizures. The team prepares hypertonic saline. Which of the following statements about 3% sodium chloride most accurately describes its sodium content, the appropriate acute dosing strategy for symptomatic hyponatremia, and the limitation of the Adrogue-Madias equation?
A) 3% sodium chloride contains 513 mEq/L of sodium; for symptomatic acute hyponatremia, the standard approach is 100 mL IV bolus repeated up to twice if symptoms persist, targeting a 5 mEq/L rise sufficient to relieve cerebral edema; the Adrogue-Madias equation provides a starting estimate of expected sodium change per liter of infusate but is unreliable in real-time and cannot substitute for frequent serum sodium measurements
B) 3% sodium chloride contains 308 mEq/L of sodium, identical to the molar concentration of isotonic saline but at triple the volume; the dose for acute symptomatic hyponatremia is 500 mL over 1 hour; the Adrogue-Madias equation accurately predicts real-time sodium changes to within 2 mEq/L and can be used to titrate infusion rates without additional monitoring
C) 3% sodium chloride contains 154 mEq/L of sodium — triple the concentration of normal saline; for acute symptomatic hyponatremia the standard dose is 1 L given over 4 hours; the Adrogue-Madias equation is the definitive real-time monitoring tool that eliminates the need for repeat serum sodium measurements during infusion
D) 3% sodium chloride contains 900 mEq/L of sodium and is reserved for patients with serum sodium below 110 mEq/L; it must never be given as a bolus and is only administered as a slow infusion of 10–20 mL/hour with rate adjustments based on the Adrogue-Madias equation alone
E) 3% sodium chloride contains 513 mEq/L of sodium but is pharmacologically equivalent to isotonic saline for treating hyponatremia; the distinction between them is purely a matter of infusion volume, and either can be used for acute symptomatic hyponatremia at doses up to 2 L
ANSWER: A
Rationale:
3% sodium chloride contains 513 mEq/L of sodium, compared with 154 mEq/L in isotonic (0.9%) saline — making it more than three times as concentrated. For acute symptomatic hyponatremia (as in this seizing patient), the standard approach is a 100 mL IV bolus of 3% saline, which reliably produces approximately a 2 mEq/L rise in serum sodium sufficient to reduce intracranial pressure and relieve acute cerebral edema from hyponatremia. This bolus may be repeated up to twice if symptoms persist, with a target of approximately 5 mEq/L total rise. The Adrogue-Madias equation — which estimates the expected change in serum sodium per liter of infusate based on body water and infusate sodium content — is useful as a starting estimate for infusion planning but is notoriously unreliable for real-time monitoring because it does not account for ongoing urinary electrolyte losses, changes in the underlying disease process, or free water intake. Frequent serum sodium measurements (every 2–4 hours during active infusion) are mandatory.
Option B: Option B is incorrect: 3% saline contains 513 mEq/L (not 308 mEq/L); the 500 mL over 1 hour dose would deliver a vastly excessive sodium load for an acute bolus; and the Adrogue-Madias equation does not reliably predict real-time sodium changes to within 2 mEq/L — it is a planning estimate only.
Option C: Option C is incorrect: 3% saline contains 513 mEq/L (not 154 mEq/L, which is the concentration of isotonic saline); 1 L over 4 hours is not the standard acute symptomatic dosing; and the Adrogue-Madias equation cannot eliminate the need for repeat monitoring.
Option D: Option D is incorrect: 3% saline contains 513 mEq/L (not 900 mEq/L); it can and is given as a bolus for acute symptomatic hyponatremia; and the Adrogue-Madias equation alone is insufficient for titration without concurrent serum sodium monitoring.
Option E: Option E is incorrect: 3% saline and isotonic saline are pharmacologically distinct — their difference in sodium concentration (513 vs. 154 mEq/L) means that isotonic saline cannot correct hyponatremia in SIADH and may paradoxically worsen it; they are not equivalent treatments for hyponatremia.
7. A 63-year-old man with heart failure and euvolemic hyponatremia (serum Na 126 mEq/L) attributed to SIADH does not respond adequately to fluid restriction. The team considers tolvaptan. Which of the following accurately characterizes tolvaptan's receptor selectivity, mechanism of action, and the critical contraindication that must be assessed before prescribing?
A) Tolvaptan selectively antagonizes V1a vasopressin receptors on vascular smooth muscle, reducing systemic vascular resistance and increasing renal blood flow, which promotes urinary sodium excretion and corrects hyponatremia; it is contraindicated in patients with pulmonary hypertension
B) Tolvaptan is a non-selective vasopressin antagonist at both V1a and V2 receptors; it produces aquaresis by blocking collecting duct water reabsorption and vasoconstriction by blocking V1a receptors; it is contraindicated in patients with elevated serum creatinine above 1.5 mg/dL
C) Tolvaptan selectively antagonizes V2 vasopressin receptors in the collecting duct, blocking ADH-mediated AQP2 insertion and producing electrolyte-free water excretion (aquaresis); it is contraindicated in hypovolemic hyponatremia and must be initiated only in a monitored inpatient setting due to unpredictable correction rates
D) Tolvaptan is an agonist at V2 vasopressin receptors that produces a paradoxical aquaretic effect by desensitizing the receptor and reducing cAMP-mediated AQP2 insertion; it is contraindicated in patients with serum sodium above 125 mEq/L because correction is too rapid at higher baseline sodium levels
E) Tolvaptan antagonizes both V2 receptors in the collecting duct and aquaporin-3 channels in the basolateral membrane simultaneously, producing aquaresis; it is contraindicated in hypervolemic hyponatremia but indicated for hypovolemic hyponatremia where water excretion will restore volume balance
ANSWER: C
Rationale:
Tolvaptan is a selective V2 vasopressin receptor antagonist. In the collecting duct, V2 receptor activation by ADH normally triggers adenylate cyclase → cAMP → protein kinase A → phosphorylation and apical membrane insertion of AQP2 (aquaporin-2) water channels, allowing water reabsorption. Tolvaptan blocks V2 receptors, preventing AQP2 insertion and producing aquaresis — excretion of electrolyte-free water without proportional sodium loss. This selectively raises serum sodium in ADH-driven hyponatremic states. Two critical safety constraints govern its use: (1) tolvaptan is absolutely contraindicated in hypovolemic hyponatremia, where free water excretion would further deplete intravascular volume and precipitate hemodynamic collapse; (2) it must be initiated only in a monitored inpatient setting because sodium correction rates can be rapid and unpredictable, risking ODS if unchecked. Conivaptan (IV) is non-selective (V1a/V2); tolvaptan (oral) is V2-selective.
Option A: Option A is incorrect: tolvaptan acts on V2 receptors in the collecting duct, not V1a receptors on vascular smooth muscle; V1a antagonism is a property of conivaptan; tolvaptan does not correct hyponatremia by promoting urinary sodium excretion — it promotes free water excretion (aquaresis).
Option B: Option B is incorrect: tolvaptan is V2-selective, not non-selective; conivaptan is the V1a/V2 non-selective agent; elevated creatinine alone is not the critical contraindication — hypovolemic status is.
Option D: Option D is incorrect: tolvaptan is an antagonist, not an agonist, at V2 receptors; agonism would worsen hyponatremia by enhancing AQP2 insertion; the contraindication in hypovolemic hyponatremia is based on volume depletion risk, not baseline sodium level.
Option E: Option E is incorrect: tolvaptan blocks V2 receptors, not aquaporin-3 basolateral channels; AQP3 is not a target of any currently approved vaptan; the contraindication profile is inverted — tolvaptan is contraindicated in hypovolemic hyponatremia, not in hypervolemic hyponatremia.
8. A 52-year-old woman is diagnosed with SIADH from a pulmonary process. Her serum sodium is 128 mEq/L and she is neurologically intact with mild nausea. Which of the following most accurately describes the pharmacological management hierarchy for stable, non-symptomatic SIADH, and the role of urea as an alternative agent?
A) Hypertonic 3% saline is the first-line treatment for all SIADH regardless of symptom severity; fluid restriction is reserved for patients who cannot tolerate intravenous access, and vaptans are contraindicated due to unpredictable correction rates in outpatient settings
B) Vaptans (tolvaptan or conivaptan) are the first-line pharmacological treatment for all SIADH and should be started immediately on diagnosis; fluid restriction is only used when vaptans are unavailable or contraindicated; hypertonic saline is never indicated in euvolemic hyponatremia
C) Demeclocycline, a tetracycline antibiotic that induces nephrogenic diabetes insipidus, is the current first-line pharmacological agent for SIADH; fluid restriction and vaptans are second- and third-line respectively and are only used when demeclocycline fails
D) Loop diuretics combined with oral sodium chloride tablets are the first-line treatment for stable SIADH because furosemide prevents urinary sodium retention and the sodium tablets replete the urinary losses; vaptans and fluid restriction are reserved for diuretic-refractory cases
E) Fluid restriction to 800–1000 mL total daily fluid intake is the cornerstone of management for stable, non-symptomatic SIADH; urea (15–30 g/day orally) is an underused alternative that creates an osmotic gradient promoting water excretion without affecting sodium; vaptans are added when fluid restriction fails; hypertonic saline is reserved for acute severe or symptomatic hyponatremia
ANSWER: E
Rationale:
For stable, neurologically intact SIADH with mild-to-moderate hyponatremia, fluid restriction to 800–1000 mL total daily fluid intake is the cornerstone treatment. This is the safest and most cost-effective intervention — it reduces free water intake below the rate of urinary water excretion, allowing serum sodium to rise gradually. Urea is an underused but effective oral agent: administered at 15–30 g/day, it creates an osmotic gradient in the renal tubular lumen and collecting duct that promotes electrolyte-free water excretion (similar in principle to aquaresis) without affecting sodium balance. Its principal limitation is palatability — it is bitter and often dissolved in orange juice or mixed with food to improve compliance. Vaptans (tolvaptan orally, conivaptan IV) are added when fluid restriction is inadequate, but must be initiated in monitored inpatient settings. Hypertonic saline is reserved for acute severe hyponatremia with neurological symptoms (seizures, obtundation), not stable mild-to-moderate SIADH.
Option A: Option A is incorrect: hypertonic saline is not first-line for stable, asymptomatic SIADH; fluid restriction is the appropriate first step; vaptans are not categorically contraindicated in outpatient settings but inpatient initiation is required.
Option B: Option B is incorrect: vaptans are not first-line for all SIADH; fluid restriction is the initial intervention for stable, non-symptomatic cases; vaptans are reserved for fluid restriction failure; the claim that hypertonic saline is never indicated in euvolemic hyponatremia is incorrect — it is used for acute severe symptomatic cases.
Option C: Option C is incorrect: demeclocycline was historically used for chronic SIADH (it induces NDI by inhibiting ADH-mediated cAMP signaling) but is no longer considered first-line; it has been largely supplanted by vaptans; fluid restriction remains the initial therapy.
Option D: Option D is incorrect: loop diuretics plus sodium tablets is an approach sometimes used in resistant SIADH to increase free water clearance, but it is not first-line; the correct first step is simple fluid restriction, not diuresis.
9. A 38-year-old woman with type 1 diabetes presents with nausea, vomiting, and arterial blood gas showing pH 7.18, HCO₃⁻ 9 mEq/L, PaCO₂ 22 mmHg. Serum electrolytes: Na 136 mEq/L, Cl 98 mEq/L, K 5.1 mEq/L. A second patient, a 55-year-old man with diarrhea for 5 days, has pH 7.28, HCO₃⁻ 14 mEq/L, Na 140 mEq/L, Cl 116 mEq/L. Which of the following correctly calculates the anion gap (AG) for each patient and identifies the correct acid-base category and its implication for bicarbonate therapy?
A) Patient 1 AG = 29 mEq/L (high anion gap); Patient 2 AG = 10 mEq/L (normal anion gap); bicarbonate therapy is strongly indicated for Patient 1 because high anion gap acidosis always requires exogenous alkali to neutralize the accumulated unmeasured anion
B) Patient 1 AG = 29 mEq/L, indicating high anion gap metabolic acidosis from an unmeasured anion (consistent with diabetic ketoacidosis); Patient 2 AG = 10 mEq/L, indicating normal anion gap metabolic acidosis consistent with gastrointestinal bicarbonate loss; bicarbonate therapy is the mainstay for the non-anion gap disorder (type 2 RTA, GI losses) but is generally avoided in high anion gap acidosis from DKA or lactic acidosis due to paradoxical CNS acidosis and other risks
C) Patient 1 AG = 29 mEq/L (high anion gap); Patient 2 AG = 26 mEq/L (high anion gap); both patients have the same category of metabolic acidosis and should both be treated with insulin and IV fluids without bicarbonate supplementation
D) Patient 1 AG = 39 mEq/L (high anion gap); Patient 2 AG = 10 mEq/L (normal anion gap); in high anion gap acidosis, the anion gap magnitude directly correlates with the required bicarbonate dose, and supplementation should begin when the AG exceeds 30 mEq/L
E) Patient 1 AG = 29 mEq/L; Patient 2 AG = 10 mEq/L; both values are within the normal range (normal AG ≤ 30 mEq/L), and neither patient requires any specific pharmacological intervention for their acid-base status beyond treating the underlying condition
ANSWER: B
Rationale:
The anion gap is calculated as AG = Na − (Cl + HCO₃). Patient 1: 136 − (98 + 9) = 29 mEq/L — markedly elevated above the normal ceiling of 12 mEq/L, indicating a high anion gap metabolic acidosis (HAGMA) caused by an unmeasured anion; in this context (type 1 diabetes, nausea, vomiting, compensatory hypocapnia), diabetic ketoacidosis (DKA) is the diagnosis, with beta-hydroxybutyrate as the unmeasured anion. Patient 2: 140 − (116 + 14) = 10 mEq/L — normal anion gap, indicating a normal anion gap metabolic acidosis (NAGMA) where bicarbonate is lost or fails to be regenerated without accumulation of an unmeasured anion; 5 days of diarrhea causes gastrointestinal bicarbonate loss (stool bicarbonate content is high), producing hyperchloremic NAGMA. The therapeutic implication is critical: bicarbonate therapy is the mainstay for NAGMA (GI bicarbonate loss, RTA types 1 and 2) because the primary defect is bicarbonate deficit without an underlying acid-generating process. Bicarbonate is generally avoided in DKA and lactic acidosis because the buffering reaction generates CO₂ that crosses the BBB and causes paradoxical CSF acidosis, and insulin plus IV fluids address the DKA's ketoacidosis directly.
Option A: Option A is incorrect: while both AG calculations are correct, the therapeutic conclusion is wrong — high anion gap acidosis from DKA does not universally require exogenous bicarbonate; insulin and fluids are the primary treatment, and bicarbonate is generally avoided in DKA.
Option C: Option C is incorrect: Patient 2's AG calculates to 10 mEq/L (140 − 116 − 14 = 10), not 26 mEq/L; only Patient 1 has HAGMA; the therapeutic approach for diarrhea-induced NAGMA is not identical to DKA management.
Option D: Option D is incorrect: Patient 1's AG is 29 mEq/L (136 − 98 − 9 = 29), not 39 mEq/L; AG magnitude does not directly determine bicarbonate dose in a linear titration formula; and bicarbonate is not routinely started when AG exceeds 30 mEq/L in DKA.
Option E: Option E is incorrect: the normal AG ceiling is 12 mEq/L (not 30 mEq/L); Patient 1's AG of 29 mEq/L is markedly abnormal and represents a clinically significant HAGMA requiring urgent treatment.
10. A 60-year-old man with CKD stage 3b and serum HCO₃⁻ of 20 mEq/L is seen in nephrology clinic. A second patient, a 44-year-old woman, has type 1 distal renal tubular acidosis (RTA) with urine pH of 6.2 despite systemic acidemia and recurrent nephrolithiasis. Which of the following correctly identifies the bicarbonate therapy indication and dose requirement for each patient, and the risk that limits bicarbonate use in high anion gap metabolic acidosis?
A) CKD patient requires oral bicarbonate only when serum HCO₃⁻ falls below 15 mEq/L; type 1 RTA requires 5–15 mEq/kg/day because the proximal tubule wastes all supplemented bicarbonate; paradoxical CNS acidosis from bicarbonate in HAGMA is caused by bicarbonate crossing the BBB faster than CO₂
B) CKD patient requires bicarbonate supplementation when HCO₃⁻ falls below 18 mEq/L; type 1 RTA is treated with 5–15 mEq/kg/day; paradoxical CNS acidosis does not occur with bicarbonate in any form of metabolic acidosis
C) Both CKD-associated acidosis and type 1 RTA are treated with identical doses of 1–2 mEq/kg/day oral bicarbonate; the only distinction is route of administration; paradoxical CNS acidosis from bicarbonate occurs only in respiratory acidosis, not metabolic acidosis
D) CKD-associated metabolic acidosis requires oral sodium bicarbonate when serum HCO₃⁻ falls below 22 mEq/L to slow CKD progression; type 1 distal RTA requires 1–2 mEq/kg/day of oral bicarbonate; in high anion gap metabolic acidosis, IV bicarbonate generates CO₂ that crosses the blood-brain barrier faster than bicarbonate, transiently worsening CSF acidosis even as arterial pH rises — paradoxical CNS acidosis
E) Bicarbonate supplementation in CKD is only indicated when the patient develops symptomatic acidosis (Kussmaul respirations or altered mental status) regardless of the serum HCO₃⁻ level; type 1 RTA requires emergent IV bicarbonate at 5–15 mEq/kg/day; paradoxical CNS acidosis is caused by bicarbonate directly alkalinizing the CSF and suppressing cerebral acid-sensing receptors
ANSWER: D
Rationale:
In CKD without overt RTA, metabolic acidosis from reduced net acid excretion is treated with oral sodium bicarbonate when serum HCO₃⁻ falls below 22 mEq/L; this threshold is supported by KDIGO 2024 guidelines and by evidence that acidosis at and below this level accelerates CKD progression through complement activation and tubular injury. Type 1 (distal) RTA — in which the collecting duct cannot secrete H⁺ and urine pH cannot fall below 5.5 — requires a relatively modest bicarbonate dose of 1–2 mEq/kg/day because the proximal tubule reabsorbs bicarbonate normally; the dose replaces ongoing urinary losses from defective distal acidification. By contrast, type 2 (proximal) RTA requires 5–15 mEq/kg/day because the proximal tubule itself wastes bicarbonate — any supplemented bicarbonate is excreted before it can be retained. The paradoxical CNS acidosis of IV bicarbonate in HAGMA (DKA, lactic acidosis) occurs because the bicarbonate buffering reaction generates CO₂, which is lipophilic and crosses the blood-brain barrier rapidly; bicarbonate crosses slowly. Within the CSF, CO₂ rehydrates to carbonic acid, lowering CSF pH even as arterial pH rises — worsening cerebral acidosis paradoxically.
Option A: Option A is incorrect: the CKD bicarbonate threshold is 22 mEq/L (not 15 mEq/L); the high bicarbonate dose of 5–15 mEq/kg/day applies to type 2 proximal RTA (not type 1 distal RTA); and the mechanism of paradoxical CNS acidosis is CO₂ crossing the BBB faster than bicarbonate (correctly stated), but the option misattributes it.
Option B: Option B is incorrect: the threshold is 22 mEq/L (not 18 mEq/L); paradoxical CNS acidosis from IV bicarbonate in HAGMA is a well-documented clinical concern and does occur.
Option C: Option C is incorrect: type 1 and type 2 RTA require different doses (1–2 vs. 5–15 mEq/kg/day respectively) because of fundamentally different tubular defects; paradoxical CNS acidosis is a concern in metabolic (specifically high anion gap) acidosis, not only respiratory acidosis.
Option E: Option E is incorrect: the indication for bicarbonate in CKD is based on the serum HCO₃⁻ threshold of 22 mEq/L, not symptom onset; type 1 RTA is managed with oral, not emergent IV, bicarbonate; paradoxical CNS acidosis is caused by CO₂ generation and rapid BBB penetration, not by direct bicarbonate alkalinization of the CSF.
11. An intensivist is managing a 48-year-old man with severe combined metabolic and respiratory acidosis (pH 6.95, PaCO₂ 72 mmHg, HCO₃⁻ 15 mEq/L) on mechanical ventilation after aspiration pneumonia. She considers tromethamine (THAM) instead of sodium bicarbonate. Which of the following most accurately describes THAM's mechanism of buffering, the pharmacokinetic constraint that limits its use, and its non-acid-base adverse effects?
A) THAM accepts protons directly via its amino group without generating CO₂, avoiding the paradoxical hypercapnia that bicarbonate buffering would cause in a patient with impaired CO₂ elimination; THAM requires intact renal function for its own elimination and is contraindicated or requires dose reduction in oliguric acute kidney injury; adverse effects include hypoglycemia and respiratory depression
B) THAM accepts protons via its carboxylate group and generates bicarbonate as a byproduct, which then buffers additional acid load; it is renally eliminated and safe at standard doses in all degrees of renal impairment; adverse effects are limited to local venous irritation at the infusion site
C) THAM buffers acid by inhibiting carbonic anhydrase in the proximal tubule, increasing urinary HCO₃⁻ excretion and lowering urinary pH to enhance net acid excretion; it is hepatically metabolized and does not require dose adjustment for renal impairment; hypocalcemia is its primary adverse effect
D) THAM is a competitive antagonist at bicarbonate transporters on erythrocyte membranes, increasing CO₂ transport capacity in the blood and improving respiratory elimination of acid equivalents; renal function does not affect its elimination because it is fully protein-bound; it does not cause hypoglycemia
E) THAM acts identically to sodium bicarbonate but without the sodium load; both generate CO₂ as a buffering byproduct, both require hepatic activation before systemic buffering begins, and both are contraindicated in combined metabolic and respiratory acidosis
ANSWER: A
Rationale:
Tromethamine (THAM) is an aminoalcohol buffer that directly accepts protons (H⁺) via its amine group (R-NH₂ + H⁺ → R-NH₃⁺), producing a protonated THAM molecule without generating carbon dioxide. This CO₂-neutral mechanism is the critical advantage over sodium bicarbonate in patients with combined metabolic and respiratory acidosis and impaired CO₂ elimination: the bicarbonate buffering reaction (HCO₃⁻ + H⁺ → H₂CO₃ → CO₂ + H₂O) would generate additional CO₂ that cannot be adequately excreted, worsening hypercapnia and potentially worsening total acidosis. THAM also contains no sodium, relevant when sodium loading is a concern. The critical pharmacokinetic constraint is that THAM is renally eliminated; in oliguric or anuric AKI, THAM accumulates and can cause hypoglycemia (by stimulating insulin release) and respiratory depression (by excessive buffering of the brainstem's CO₂-sensitive chemoreceptor drive). These toxicities require cautious use or avoidance when renal function is compromised.
Option B: Option B is incorrect: THAM does not generate bicarbonate as a byproduct of buffering; it accepts protons directly without generating any secondary acidic or alkaline byproduct; it is renally eliminated and is NOT safe at standard doses in severe renal impairment.
Option C: Option C is incorrect: THAM does not inhibit carbonic anhydrase; carbonic anhydrase inhibition is the mechanism of acetazolamide; THAM is not hepatically metabolized; hypocalcemia is the primary adverse effect of foscarnet (which chelates ionized calcium), not THAM.
Option D: Option D is incorrect: THAM does not act as a competitive antagonist at bicarbonate transporters on erythrocytes; it is a systemic proton acceptor; THAM is not protein-bound and renal function substantially affects its elimination.
Option E: Option E is incorrect: THAM and bicarbonate are mechanistically distinct — only bicarbonate generates CO₂ as a buffering byproduct; THAM is CO₂-neutral; THAM does not require hepatic activation; THAM (unlike bicarbonate) is appropriate in combined metabolic and respiratory acidosis when CO₂ generation must be avoided.
12. Two patients present with metabolic alkalosis. Patient 1 is a 29-year-old woman with bulimia nervosa and chronic vomiting; urine chloride is 6 mEq/L, serum pH 7.54, HCO₃⁻ 36 mEq/L, K⁺ 2.7 mEq/L. Patient 2 is a 55-year-old man with hypertension, serum pH 7.51, HCO₃⁻ 33 mEq/L, K⁺ 3.0 mEq/L; urine chloride is 38 mEq/L. Which of the following correctly classifies each patient's metabolic alkalosis and identifies the appropriate pharmacological treatment for each?
A) Patient 1 has chloride-resistant metabolic alkalosis (high urine Cl); treatment is spironolactone or adrenalectomy to suppress autonomous aldosterone; Patient 2 has chloride-responsive alkalosis (low urine Cl); treatment is isotonic saline and KCl
B) Both patients have chloride-responsive metabolic alkalosis because both have serum bicarbonate above 30 mEq/L; treatment is identical — isotonic saline and KCl repletion — with the dose titrated to the degree of elevation above normal
C) Patient 1 has chloride-responsive metabolic alkalosis (urine Cl below 20 mEq/L) caused by HCl loss from vomiting with secondary chloride and volume depletion; treatment is isotonic saline and KCl repletion; Patient 2 has chloride-resistant metabolic alkalosis (urine Cl above 20 mEq/L) consistent with ongoing aldosterone-driven collecting duct H⁺ secretion; treatment requires addressing the underlying aldosterone excess — mineralocorticoid receptor antagonism or surgical resection
D) Patient 1 has euvolemic metabolic alkalosis requiring tolvaptan to produce aquaresis and reduce extracellular bicarbonate concentration; Patient 2 has hypervolemic metabolic alkalosis requiring acetazolamide to force urinary bicarbonate wasting; urine chloride does not distinguish between these etiologies
E) Both patients have chloride-resistant metabolic alkalosis; treatment for both is acetazolamide to inhibit carbonic anhydrase and force urinary bicarbonate excretion; the urine chloride difference between the two patients reflects dietary sodium intake rather than etiological mechanism
ANSWER: C
Rationale:
Urine chloride is the pivotal diagnostic test for classifying metabolic alkalosis. A urine chloride below 20 mEq/L indicates chloride-responsive alkalosis: the kidney is avidly conserving chloride because of chloride and volume depletion. In Patient 1, chronic vomiting causes loss of HCl from gastric secretions, producing chloride depletion, secondary hyperaldosteronism from volume contraction, and hypokalemia — all of which sustain the alkalosis. Treatment removes all three maintaining stimuli simultaneously: isotonic saline restores volume (suppressing RAAS) and repletes chloride (restoring the chloride-bicarbonate exchanger), while KCl replaces potassium (stopping potassium-driven H⁺ secretion in the collecting duct). A urine chloride above 20 mEq/L indicates chloride-resistant alkalosis: the kidney continues to excrete chloride because ongoing aldosterone-driven sodium reabsorption maintains collecting duct H⁺ and K⁺ secretion independent of volume status. Patient 2's hypertension with hypokalemia and urine Cl 38 mEq/L is consistent with primary hyperaldosteronism; saline will not correct the alkalosis because autonomous aldosterone secretion continues regardless of volume expansion.
Option A: Option A is incorrect: the urine chloride classifications are inverted — Patient 1 has urine Cl 6 mEq/L (below 20 = chloride-responsive), not chloride-resistant; Patient 2 has urine Cl 38 mEq/L (above 20 = chloride-resistant), not chloride-responsive; the treatments are therefore also inverted.
Option B: Option B is incorrect: the serum bicarbonate level does not determine the chloride-responsive vs. chloride-resistant classification — urine chloride does; both etiologies can produce identical serum bicarbonate elevations but require completely different treatments.
Option D: Option D is incorrect: tolvaptan produces aquaresis (free water excretion) and does not lower serum bicarbonate; acetazolamide is appropriate for chloride-resistant alkalosis in volume-overloaded patients (e.g., heart failure) but not as a blanket treatment without addressing the underlying aldosterone excess.
Option E: Option E is incorrect: both patients do not have chloride-resistant alkalosis — Patient 1's urine Cl of 6 mEq/L clearly indicates chloride-responsive disease; urine chloride reflects tubular chloride handling, not dietary sodium intake.
13. A 71-year-old man with decompensated heart failure and volume overload has serum bicarbonate of 35 mEq/L, pH 7.50, and is receiving IV furosemide. The team recognizes that his contraction alkalosis is impairing loop diuretic responsiveness. They cannot give isotonic saline to correct the alkalosis. Acetazolamide is added. Which of the following best explains how acetazolamide corrects the metabolic alkalosis in this patient, and what evidence supports its use in this context?
A) Acetazolamide inhibits aldosterone binding to the mineralocorticoid receptor in the collecting duct, reducing ENaC-mediated sodium reabsorption and the secondary H⁺ secretion that perpetuates the alkalosis; the ADVOR trial demonstrated that this aldosterone-blocking mechanism improved decongestion in hospitalized heart failure patients
B) Acetazolamide stimulates Na-K-2Cl cotransporter activity in the thick ascending limb, increasing urinary chloride excretion and restoring the chloride gradient needed for collecting duct bicarbonate secretion; its use in heart failure is supported by the ADVOR trial showing improved urine output without worsening electrolytes
C) Acetazolamide blocks the V2 vasopressin receptor in the collecting duct, producing aquaresis that dilutes the elevated serum bicarbonate; the ADVOR trial confirmed this mechanism produces a greater reduction in bicarbonate than loop diuretics alone
D) Acetazolamide inhibits renal H⁺/K⁺-ATPase in the collecting duct intercalated cells, preventing hydrogen ion secretion and potassium reabsorption simultaneously and lowering serum bicarbonate; it is indicated in all metabolic alkalosis regardless of volume status because it does not add sodium load
E) Acetazolamide inhibits carbonic anhydrase in the proximal convoluted tubule, impairing bicarbonate reabsorption and forcing urinary bicarbonate wasting, thereby lowering serum bicarbonate without sodium loading; the ADVOR trial demonstrated that acetazolamide added to IV loop diuretics improved decongestion rates in hospitalized heart failure patients, in part through restoration of loop diuretic efficacy by correcting the alkalosis
ANSWER: E
Rationale:
Acetazolamide inhibits carbonic anhydrase (CA) in the proximal convoluted tubule (PCT). CA normally catalyzes the luminal reaction HCO₃⁻ + H⁺ → H₂CO₃ → CO₂ + H₂O, allowing CO₂ to diffuse into PCT cells where it is reconverted to HCO₃⁻ for reabsorption. When CA is inhibited, this reconversion is impaired, bicarbonate cannot be reclaimed from the filtrate, and it is excreted in the urine. The resulting urinary bicarbonate wasting lowers serum bicarbonate toward normal without adding sodium — making acetazolamide the appropriate agent in volume-overloaded patients with metabolic alkalosis who cannot tolerate saline. Metabolic alkalosis in heart failure is clinically important because alkalosis impairs loop diuretic responsiveness (reducing urinary Na⁺ and water excretion), so correcting it with acetazolamide restores diuretic efficacy. The ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial confirmed that acetazolamide added to standard IV loop diuretics significantly improved decongestion outcomes in hospitalized heart failure patients.
Option A: Option A is incorrect: acetazolamide acts on carbonic anhydrase in the PCT, not on the mineralocorticoid receptor; aldosterone receptor antagonism is the mechanism of spironolactone and eplerenone; the ADVOR trial demonstrated carbonic anhydrase-mediated bicarbonate wasting as the mechanism, not aldosterone blockade.
Option B: Option B is incorrect: the Na-K-2Cl cotransporter in the thick ascending limb is the target of loop diuretics (furosemide, bumetanide, torsemide), not acetazolamide; acetazolamide does not stimulate this transporter.
Option C: Option C is incorrect: V2 receptor antagonism producing aquaresis is the mechanism of vaptans (tolvaptan, conivaptan), not acetazolamide; acetazolamide produces bicarbonate-rich urine (bicarbonaturia), not electrolyte-free water excretion.
Option D: Option D is incorrect: H⁺/K⁺-ATPase in collecting duct intercalated cells is not the target of acetazolamide; this transporter is involved in distal acidification and potassium reabsorption and is not the site of carbonic anhydrase action; acetazolamide is not indicated in all metabolic alkalosis regardless of volume status — in chloride-responsive, volume-depleted patients, saline is preferred.
14. A 41-year-old man with bipolar disorder on long-term lithium develops polyuria of 8 liters per day. Water deprivation testing followed by desmopressin administration produces no rise in urine osmolality. Which of the following correctly identifies the cellular mechanism by which lithium causes nephrogenic diabetes insipidus (NDI) and explains why amiloride is the preferred treatment?
A) Lithium competitively blocks V2 vasopressin receptors on collecting duct principal cells, preventing ADH binding and cAMP generation; amiloride is preferred because it acts as a V2 receptor agonist that displaces lithium from the receptor and partially restores ADH-mediated AQP2 insertion
B) Lithium enters collecting duct principal cells via the epithelial sodium channel (ENaC) and accumulates intracellularly, where it inhibits adenylate cyclase, preventing vasopressin-stimulated cAMP generation and downstream AQP2 insertion; amiloride blocks ENaC, reducing lithium entry into principal cells and attenuating the intracellular adenylate cyclase inhibition
C) Lithium inhibits aquaporin-2 gene transcription in collecting duct principal cells by binding directly to the AQP2 promoter region; amiloride is preferred because it upregulates AQP2 transcription through a separate cAMP-independent pathway, compensating for the lithium-induced transcriptional suppression
D) Lithium causes NDI by activating the ROMK channel in the collecting duct, causing constitutive potassium secretion that depolarizes the principal cell membrane and prevents the voltage-gated calcium influx required for AQP2 vesicle fusion; amiloride blocks ROMK and restores the membrane potential needed for AQP2 insertion
E) Lithium inhibits Na/K-ATPase in collecting duct principal cells, preventing the sodium gradient required to drive ENaC-mediated sodium reabsorption; without sodium influx, the principal cell cannot generate the electrochemical signal for AQP2 trafficking; amiloride restores Na/K-ATPase activity by chelating the lithium ion
ANSWER: B
Rationale:
Lithium is a substrate for the epithelial sodium channel (ENaC) on the apical membrane of collecting duct principal cells — it enters the cell in place of sodium because ENaC cannot distinguish between the two monovalent cations. Once intracellular, lithium accumulates and inhibits adenylate cyclase, the enzyme responsible for converting ATP to cyclic AMP (cAMP) in response to vasopressin (ADH) binding at V2 receptors on the basolateral membrane. Without adequate cAMP, protein kinase A is not activated, AQP2 vesicles are not phosphorylated and inserted into the apical membrane, and collecting duct water permeability remains low — producing NDI that cannot be overcome by exogenous desmopressin (as confirmed in this patient's water deprivation test). Amiloride blocks ENaC on the apical membrane of principal cells, directly reducing lithium entry into the cell, thereby attenuating the intracellular adenylate cyclase inhibition and partially restoring AQP2 responsiveness to vasopressin. This mechanism also explains why thiazide diuretics reduce lithium-induced polyuria — volume contraction increases proximal sodium (and lithium) reabsorption, reducing collecting duct lithium delivery — but thiazides increase serum lithium levels and require close monitoring.
Option A: Option A is incorrect: lithium does not act at V2 receptors as a competitive antagonist; its action is intracellular (adenylate cyclase inhibition), which is why supraphysiological desmopressin cannot overcome the defect — the receptor is intact but signaling downstream of it is blocked; amiloride is not a V2 agonist.
Option C: Option C is incorrect: lithium does not bind the AQP2 gene promoter directly; its mechanism is enzymatic (adenylate cyclase inhibition), not transcriptional; amiloride does not upregulate AQP2 transcription via a cAMP-independent pathway.
Option D: Option D is incorrect: lithium does not activate ROMK; ROMK is a potassium secretory channel regulated by aldosterone and tubular flow, not lithium; membrane depolarization via potassium secretion is not the mechanism by which lithium causes NDI.
Option E: Option E is incorrect: lithium does not inhibit Na/K-ATPase as its primary mechanism of NDI; Na/K-ATPase inhibition is the mechanism of cardiac glycosides (digoxin); amiloride does not chelate lithium ions.
15. A 39-year-old immunocompromised woman receives conventional amphotericin B deoxycholate for invasive aspergillosis. After 2 weeks of therapy she develops serum K⁺ 2.4 mEq/L, serum Mg²⁺ 0.8 mg/dL, and urine pH of 6.1 that cannot be lowered despite worsening systemic acidemia. Which of the following correctly identifies the cellular mechanism producing this constellation and explains why lipid formulations substantially reduce these toxicities?
A) Amphotericin B inhibits the Na/K-2Cl cotransporter in the thick ascending limb, reducing the lumen-positive potential that normally drives passive potassium and magnesium reabsorption; lipid formulations reduce TAL drug delivery by altering tubular secretion kinetics
B) Amphotericin B chelates ionized calcium and magnesium directly in the tubular lumen, reducing their reabsorption and causing a type 2 proximal RTA pattern; lipid formulations buffer the chelation reaction, reducing the extent of luminal magnesium binding
C) Amphotericin B selectively inhibits H⁺/K⁺-ATPase in collecting duct alpha-intercalated cells, simultaneously impairing hydrogen ion secretion and potassium reabsorption; lipid formulations alter the drug's receptor binding kinetics, reducing H⁺/K⁺-ATPase inhibition at clinical doses
D) Amphotericin B inserts into mammalian renal tubular cell membranes at cholesterol-rich sites in the distal tubule and collecting duct, forming pores that increase membrane permeability to potassium and hydrogen ions; potassium leaks through the pores causing urinary wasting and hypokalemia; impaired H⁺ secretion by intercalated cells produces a type 1 distal RTA pattern; lipid formulations limit free amphotericin B exposure to tubular cells, substantially reducing membrane pore formation and the associated electrolyte toxicities
E) Amphotericin B activates the mineralocorticoid receptor constitutively in the collecting duct, mimicking primary hyperaldosteronism and driving excessive potassium and hydrogen ion secretion; lipid formulations prevent mineralocorticoid receptor binding by sequestering the drug in the lipid vehicle
ANSWER: D
Rationale:
Conventional amphotericin B deoxycholate exerts its antifungal effect by inserting into ergosterol-rich fungal cell membranes to form ion-conducting pores that disrupt membrane integrity. At concentrations reached in the renal tubular lumen, it also inserts into mammalian renal tubular cell membranes at cholesterol-rich domains — particularly in the distal tubule and collecting duct — forming similar pores. These pores increase membrane permeability to potassium ions (causing urinary potassium wasting and hypokalemia) and to hydrogen ions (impairing the H⁺ gradient required for net acid secretion by collecting duct alpha-intercalated cells, producing a type 1 distal RTA pattern with inability to lower urine pH below 5.5). Hypomagnesemia results from disruption of magnesium reabsorption in the thick ascending limb and distal tubule. Lipid formulations of amphotericin B (amphotericin B lipid complex, liposomal amphotericin B) encapsulate the drug in lipid vesicles that preferentially deliver it to fungal membranes; free drug exposure to mammalian renal tubular cells is dramatically reduced, substantially decreasing membrane pore formation and the associated electrolyte toxicities.
Option A: Option A is incorrect: amphotericin B does not inhibit the Na-K-2Cl cotransporter (NKCC2); that is the mechanism of loop diuretics; the lumen-positive potential in the TAL is not amphotericin's site of action, and pore formation in distal tubular cells (not cotransporter inhibition) produces the observed electrolyte losses.
Option B: Option B is incorrect: direct tubular lumen chelation of ionized calcium and magnesium is the mechanism of foscarnet, not amphotericin B; amphotericin causes a type 1 distal RTA (not type 2 proximal RTA) because the defect is in collecting duct H⁺ secretion, not proximal tubular bicarbonate reabsorption.
Option C: Option C is incorrect: amphotericin B does not selectively inhibit H⁺/K⁺-ATPase; its mechanism is non-selective membrane pore formation; selective enzymatic inhibition of a specific transporter is not consistent with amphotericin's membrane-disrupting pharmacology.
Option E: Option E is incorrect: amphotericin B does not activate the mineralocorticoid receptor; its tubular toxicity is a direct physical consequence of membrane pore insertion, not receptor-mediated signaling; mimicry of primary hyperaldosteronism is not the pharmacological mechanism.
16. A 57-year-old man with testicular cancer completed four cycles of cisplatin-based chemotherapy 6 months ago. His renal function has normalized, but he continues to require weekly IV potassium replacement for persistent serum K⁺ of 3.0 mEq/L despite oral supplementation of 80 mEq/day. Serum magnesium is 0.6 mg/dL. Which of the following best explains the molecular mechanism linking cisplatin-induced hypomagnesemia to refractory hypokalemia, and identifies the correct management priority?
A) Cisplatin damages TRPM6 channels in the distal convoluted tubule, causing persistent urinary magnesium wasting; hypomagnesemia depletes intracellular magnesium, removing the Mg²⁺ block of the ROMK channel from the cytoplasmic side, causing constitutive renal potassium secretion that cannot be corrected by potassium supplementation alone until magnesium is aggressively repleted
B) Cisplatin causes refractory hypokalemia by permanently suppressing aldosterone synthesis in the adrenal cortex, reducing ENaC-mediated sodium reabsorption and ROMK-mediated potassium secretion simultaneously; magnesium replacement has no role in correcting this aldosterone-deficient hypokalemia
C) Cisplatin inhibits Na/K-ATPase in skeletal muscle cells, impairing the ability of muscle to take up potassium from the extracellular space; the resulting redistribution hypokalemia is unresponsive to standard supplementation; magnesium levels are irrelevant to this mechanism
D) Cisplatin causes refractory hypokalemia through SIADH-mediated hyponatremia, which dilutes serum potassium by expanding total body water; correcting the hyponatremia with fluid restriction will simultaneously normalize serum potassium without requiring magnesium supplementation
E) Cisplatin depletes intracellular potassium stores in renal tubular cells by inhibiting the ROMK channel directly; this reduces tubular potassium recycling in the thick ascending limb, impairing the lumen-positive potential and worsening magnesium reabsorption as a secondary consequence; potassium repletion should precede magnesium repletion
ANSWER: A
Rationale:
Cisplatin selectively damages TRPM6 (transient receptor potential melastatin 6), the primary apical magnesium entry channel in the distal convoluted tubule (DCT), causing persistent urinary magnesium wasting that can last months to years even after completion of chemotherapy and normalization of serum creatinine. Hypomagnesemia depletes intracellular magnesium, which normally provides a voltage-dependent intracellular block of the ROMK (renal outer medullary potassium channel) from the cytoplasmic side. ROMK is the principal potassium secretory channel in the collecting duct and thick ascending limb; without the intracellular Mg²⁺ block, ROMK remains constitutively open and continuously secretes potassium into the tubular lumen regardless of systemic potassium status. This is the molecular basis of refractory hypokalemia: potassium is continuously excreted through unblocked ROMK channels no matter how much is supplemented orally or IV. The management priority is aggressive IV magnesium sulfate replacement — typically 1–2 g IV over 30–60 minutes, repeated as needed to raise serum magnesium above 1.5–2.0 mg/dL — before expecting potassium supplementation to be retained.
Option B: Option B is incorrect: cisplatin does not permanently suppress aldosterone synthesis in the adrenal cortex; its primary renal toxicity is tubular, targeting TRPM6 in the DCT and causing proximal tubular injury (not adrenocortical injury); reduced aldosterone would cause potassium retention (hyperkalemia), not urinary wasting.
Option C: Option C is incorrect: cisplatin does not inhibit Na/K-ATPase in skeletal muscle as its mechanism of hypokalemia; Na/K-ATPase inhibition is the mechanism of cardiac glycosides; serum magnesium is directly relevant to the hypokalemia mechanism via ROMK channel regulation.
Option D: Option D is incorrect: cisplatin-induced hypokalemia is not mediated through SIADH or dilutional mechanisms; it is a urinary wasting disorder caused by TRPM6 damage and ROMK dysregulation; fluid restriction for hyponatremia would not correct the renal potassium wasting.
Option E: Option E is incorrect: cisplatin does not inhibit ROMK directly; ROMK's constitutive opening is a consequence of magnesium depletion losing the cytoplasmic block — a downstream effect of TRPM6 damage, not a direct ROMK inhibition; potassium repletion without magnesium repletion will be ineffective because ROMK remains open.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.